.jpg?format=webp&width=780)
The DBLG1 system is a hybrid closed-loop solution for patients with type 1 diabetes and was commercialized in Germany in 2021. A study was conducted to assess the glycemic outcomes among the first 3706 users of the DBLG1 system. The study showed that the system improved glycemic control and reduced the risk of hypoglycemia in adult patients with type 1 diabetes. Therefore, the authors concluded that the DBLG1 system is relevant for achieving standards of care in adult patients with type 1 diabetes.
Like
Save
Share